secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-09-01T13:26:31+00:00
Accession:  0001140361-26-035195
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics completes $10B acquisition by Vertex at $85/share
-----------------------------------------------------------

- Merger completed Sept 1, 2026; Crinetics shareholders receive $85.00 per share cash.
- Aggregate consideration ~$10.0B, funded via Vertex cash and term loan borrowings.
- Crinetics common stock to be delisted from Nasdaq; Form 25 and Form 15 filings to follow.
- All prior directors resigned; Charles Wagner named sole director and President; Prasanna Thombre and Omar White as Treasurer and Secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/ef20081409_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer